Approved by the United States! A first in 18 years

class = “cf”>

According to the written statement from the FDA, the Alzheimer’s disease drug “aducanumab”, which is in the experimental stage and developed by Biogen, has been approved for use in the early stages.

The drug in question slows the progression of mild cognitive impairment that appears in the early stages of Alzheimer’s disease. Experts stress that the purpose of the drug is to slow the progression of the disease rather than relieve symptoms.

SCIENTISTS HAVE DECLARED “NO SUFFICIENT EVIDENCE” FOR THE EFFECTIVENESS OF THE MEDICINAL PRODUCT

Thus, the FDA approved the use of a drug against Alzheimer’s disease for the first time since 2003. On the other hand, the approval has sparked discussions in the scientific world.

Scientists reviewing Biogen’s application for approval for use prepared a report last year indicating that there was not enough evidence to show that the drug was effective in treatment.

Bigpara for cryptocurrency markets

Bigpara for cryptocurrency markets

Add a Comment